Biogen counts on drugs from Apellis deal to patch Leqembi's slow sales

Chris Viehbacher, Biogen CEO (Sarah Merians Photography for Endpoints News) July 23, 2026 10:00 AM EDT Pharma Bio­gen bets new­ly ac­quired Apel­lis can pa­per over Leqem­bi's dis­ap­point­ing sales in­to 2027 Max Gelman Senior Editor It’s no se­cret that sales of Leqem­bi have been dis­ap­point­ing. First ap­proved in 2023, the Alzheimer’s drug from Ei­sai and Bio­gen launched short­ly af­ter Chris … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER